Brain SPECT shows signs of growth

Article

Shipments of Spectamine were interrupted at a most inopportunetime. Just as clinical demand for single-photon emission computedtomography brain agents was beginning to pick up, supplier IMPhas been forced to seek financial and manufacturing partners

Shipments of Spectamine were interrupted at a most inopportunetime. Just as clinical demand for single-photon emission computedtomography brain agents was beginning to pick up, supplier IMPhas been forced to seek financial and manufacturing partners toresurrect Spectamine. Contract production of the agent was shutdown by Medi-Physics this year after IMP of Schaumburg, IL, couldn'tpay the bills (SCAN 6/17/92).

Iodine-labeled Spectamine is one of only two SPECT brain radiopharmaceuticalsapproved by the Food and Drug Administration. The other, technetium-taggedCeretec, is manufactured by Medi-Physics' parent Amersham. A secondtechnetium brain agent, Du Pont's Neurolite, will likely be thenext agent to hit the U.S. market.

Although neurological multidetector SPECT cameras have beenaround for seven or eight years, most SPECT imaging activity hasbeen on the cardiac side. Demand for brain SPECT cameras has beenincreasing of late, however, as clinical experience with the agentsgrows.

"The first three-head camera was shown in 1985. Now, in1992, people are actually buying the three-head. They are buyingit for the promise of neurology," said James L. Besett, generalmanager of Picker International's nuclear medicine division.

Developments of neurological therapies are also stimulatingthe brain SPECT market, said IMP president James F. Lamb. Therapeuticagents for stroke and Alzheimer's disease, for instance, are inclinical trials. The nuclear medicine market will benefit fromthe need to monitor and evaluate these therapies, he said.

Other forces driving the market are advances in psychiatry,where drugs are already approved, and increased use of brain SPECTin trauma applications, Lamb said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.